The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics• A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation• Stanford’s AI Designed Bacteriophages: Ushering in the Next Phase in IP Strategy for Phage Companies?• Breathing Engineered Bacteria: A New Approach to Treating Lung Disease• Vedanta Biosciences Secures $60 Million in Funding Ahead of Pivotal Phase 3 Data• Gut fungi may hold the key to treating Asthma worldwide•

Category: Clinical & Manufacturing

From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics
Clinical & Manufacturing

From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics

SEP 4, 2026
Vedanta Biosciences Secures $60 Million in Funding Ahead of Pivotal Phase 3 Data
Clinical & Manufacturing

Vedanta Biosciences Secures $60 Million in Funding Ahead of Pivotal Phase 3 Data

AUG 7, 2026
Engineered gut bacteria therapy emerges as scalable potential alternative to FMT following clinical trial
Basic & Discovery Research

Engineered gut bacteria therapy emerges as scalable potential alternative to FMT following clinical trial

JUN 8, 2026
EnteroBiotix Secures £19m to Initiate Phase 2b Clinical Trial for IBS
Clinical & Manufacturing

EnteroBiotix Secures £19m to Initiate Phase 2b Clinical Trial for IBS

APR 30, 2026
Freya Biosciences announces positive Phase 1 data for IVF-related embryo implantation failure
Clinical & Manufacturing

Freya Biosciences announces positive Phase 1 data for IVF-related embryo implantation failure

APR 16, 2026
Multi-strain probiotic therapy shows promise in preventing bacterial vaginosis recurrence
Clinical & Manufacturing

Multi-strain probiotic therapy shows promise in preventing bacterial vaginosis recurrence

MAR 24, 2026
EnteroBiotix announces positive Phase 2 results for potential first-in-class, oral, full-spectrum microbiome therapy for IBS
Clinical & Manufacturing

EnteroBiotix announces positive Phase 2 results for potential first-in-class, oral, full-spectrum microbiome therapy for IBS

JAN 8, 2026
Whitepaper: Oral Drug Delivery of Live Biotherapeutics: From Development to Clinical Trial with EUDRACAP® Select
Clinical & Manufacturing

Whitepaper: Oral Drug Delivery of Live Biotherapeutics: From Development to Clinical Trial with EUDRACAP® Select

NOV 19, 2025
Siolta Therapeutics Reports Positive Phase 2 Results from the ADORED Study
Clinical & Manufacturing

Siolta Therapeutics Reports Positive Phase 2 Results from the ADORED Study

NOV 17, 2025
Concerto Biosciences Announces Positive Topline Results from Phase 1b Clinical Trial of ENS-002 in Patients with Atopic Dermatitis
Clinical & Manufacturing

Concerto Biosciences Announces Positive Topline Results from Phase 1b Clinical Trial of ENS-002 in Patients with Atopic Dermatitis

OCT 29, 2025
Bloom Science Demonstrates Durable Weight Loss in Overweight Individuals in Phase 1 Trial of BL-001 
Clinical & Manufacturing

Bloom Science Demonstrates Durable Weight Loss in Overweight Individuals in Phase 1 Trial of BL-001 

MAR 7, 2025